Protagonist reports Q4 2021 net loss $36.9M; cash $326.9M; rusfertide Phase 3 to start Q1 2022

Protagonist Therapeutics, Inc

2022-FY EPS reported -$2.71 revenue$27,357,000

Net loss Q4 2021 $36.9M ($0.77/share) vs $18.9M ($0.48/share) in Q4 2020; full year loss $125.6M ($2.71/share) vs $66.2M ($1.92/share).
Cash, equivalents and marketable securities $326.9M as of Dec 31, 2021; expected to fund operations through 2024.
Phase 3 VERIFY study of rusfertide in polycythemia vera to initiate Q1 2022; topline PN-943 Phase 2 UC data expected Q2 2022.
Phase 2b FRONTIER 1 study of PN-235 in plaque psoriasis initiated; $25M milestone due upon dosing third patient.
R&D expenses Q4 2021 $38.4M (vs $19.5M); full year $126.0M (vs $74.5M) on advancing pipeline and employee costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.